Valneva SE:Valneva And Pfizer Complete Recruitment For Phase 2 Trial Of Lyme Disease Vaccine Candidate.Have Completed Recruitment For Phase 2 Trial, Vla15-221, Of Lyme Disease Vaccine Candidate, Vla15.Trial Builds On Previous Positive Phase 2 Trials And Includes Both Adult And Pediatric Participants.Main Safety And Immunogenicity Readout Will Be Performed Approximately One Month After Completion Of Primary Vaccination Schedule.Objective Of Trial Is To Show Safety And Immunogenicity Down To 5 Years Of Age And To Evaluate Optimal Vaccination Schedule For Use In Phase 3.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments